Ceritinib / LDK378 / 1032900-25-6
| Post Date: |
Aug 18,2016 |
| Expiry Date: |
Aug 18,2017 |
| Detailed Description: |
Cas No. :1032900-25-6
Specs:98%min
Payment Method: T/T
Ceritinib (LDK378) is a drug for the treatment of lung cancer. It is an ALK inhibitor. It was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) following treatment with crizotinib. |
| CAS Registry Number: |
|
| Synonyms: |
;LDK 378;5-chloro-n4-(2-((1-methylethyl)sulfonyl)phenyl)-n2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-2,4-pyrimidinediamine;LDK378; |
| Molecular Formula: |
C28H36ClN5O3S |
| Molecular Structure: |
|
| Company: |
Shanghai Biopharmaleader Co.,Ltd
[ China ]
|
| Contact: |
Brenda Xu |
| Tel: |
021-50180596 |
| Fax: |
021-57758967 |
| Email: |
brenda@biopharmaleader.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
